KRN5500 induces apoptosis (PCD) of myeloid leukemia cell lines and patient blasts.
The purpose of this study was to determine if KRN5500, a spicamycin derivative with a unique acyl tail, would induce programmed cell death (PCD) of myeloid leukemia cell lines and cryopreserved leukemic blasts from newly diagnosed children with acute leukemia (AL). Cells were incubated with varying concentrations (0-5 ng/ml) of KRN5500 and the percent PCD determined using a modified in situ end labeling (ISEL) technique with Klenow fragment. The percent PCD was calculated using the formula: Percent PCD (% PCD)=[number of apoptotic cells/(viable cells+apoptotic cells)]x100. DMSO (0.30% w/v) was added to the cells in culture as the positive control for PCD; the negative control was media or albumin. KRN5500 increased the amount of PCD significantly in all five of the tested cell lines; U937 41+/-1.8%, KG1a 40+/-0.3%, HEL 14+/-2.2%, HL-60 41+/-0. 9%, K562 36+/-2% (mean PCD+/-SD). Patient blasts exposed to KRN5500 had an increase in PCD when exposed to 2 ng/ml of agent from 2 to 8 h; acute myeloid leukemia patients 7.5+/-0.5% at 2 h to 43.5+/-1.6% at 8 h, and acute lymphocytic leukemia patients rose from 12.4+/-3.8% at 2 h to 29.9+/-11.6% after 8 h (mean+/-SE). Overall the PCD for the patient samples was 3.7 versus 28+/-4% at 2 and 8 h, respectively. PCD was proportional to the dose of KRN5500 and incubation time. Further pre-clinical and clinical studies are required.
Stine
K C
KC
Department of Pediatrics, University of Arkansas for Medical Sciences at Arkansas Children's Hospital, 800 Marshall St., Little Rock, AR 72202, USA. stinekimoc@exchange.uams.edu
Warren
B A
BA
Saylors
R L
RL
Becton
D L
DL
D017209:Apoptosis / Q000187:drug effects*; D002648:Child; D006801:Humans; D007951:Leukemia, Myeloid / Q000473:pathology*; D011684:Purine Nucleosides / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D011684:Purine Nucleosides; C092296:KRN 5500